Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.02 USD
Change Today 0.00 / 0.00%
Volume 285.0
MYMX On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

mymetics corp (MYMX) Snapshot

Open
$0.02
Previous Close
$0.02
Day High
$0.02
Day Low
$0.02
52 Week High
09/12/14 - $0.04
52 Week Low
01/26/15 - $0.02
Market Cap
5.8M
Average Volume 10 Days
192.0K
EPS TTM
$-0.0020
Shares Outstanding
303.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYMETICS CORP (MYMX)

Related News

No related news articles were found.

mymetics corp (MYMX) Related Businessweek News

No Related Businessweek News Found

mymetics corp (MYMX) Details

Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases. Its product pipeline consists of five proprietary vaccines in development for the prevention and treatment of human immunodeficiency virus type 1, malaria, herpes simplex virus type I and II, respiratory syncytial virus (RSV), and intra-nasal influenza. The company has collaboration agreements with RSV Corporation for the development of RSV vaccine, as well as with Texas Biomedical Research Institute. It also has a collaboration agreement with PATH Malaria Vaccine Initiative (MVI), and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases for the development and production of virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. The company was founded in 1990 and is based in Epalinges, Switzerland.

20 Employees
Last Reported Date: 08/14/15
Founded in 1990

mymetics corp (MYMX) Top Compensated Officers

Chief Executive Officer, President, Chief Ope...
Total Annual Compensation: €278.9K
Chief Scientific Officer
Total Annual Compensation: €216.0K
Compensation as of Fiscal Year 2014.

mymetics corp (MYMX) Key Developments

Mymetics Corporation Auditor Raises 'Going Concern' Doubt

Mymetics Corporation filed its 10-K on Mar 30, 2015 for the period ending Dec 31, 2014. In this report its auditor, Peterson Sullivan PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Mymetics Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Mymetics Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

PATH Malaria Vaccine Initiative Chooses Mymetics Corporation to Develop and Produce Virosome Based Vaccine Formulations for Malaria Transmission-Blocking Vaccine Candidate

Mymetics Corporation announced that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. Mymetics' proprietary virosome technology platform and its specialist virosome know-how has been selected to develop an innovative Malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). These new virosome vaccine candidates will each incorporate two different malaria parasite proteins supplied by LMIV and will be then separately tested in animal studies. The project will start in November 2014, and preclinical results are expected by early 2016. If this study is successful, the next step could be to prepare for clinical trials for a malaria transmission-blocking virosome vaccine and also explore the possibilities to combine this vaccine with other malaria vaccine candidates which are focused on other aspects of preventing malaria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYMX:US $0.02 USD 0.00

MYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYMX.
View Industry Companies
 

Industry Analysis

MYMX

Industry Average

Valuation MYMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYMETICS CORP, please visit www.mymetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.